Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice

Neuropharmacology

Volumn 86, Issue , 2014, Pages 57-66

  Klein, Caroline P ^a   Sperotto, Nathalia D M ^a   Maciel, Izaque S ^a   Leite, Carlos E ^a   Souza, Alessandra H ^a   Campos, Maria M ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

D series resolvins; Fibromyalgia; Mice; Neurotransmitters; Pregabalin; Reserpine

Indexed keywords

ANTIPAIN; ASPIRIN TRIGGERED RESOLVIN D1; BRAIN PROTEIN; DOPAMINE; GLUTAMIC ACID; PREGABALIN; RESERPINE; RESOLVIN D1; RESOLVIN D2; SEROTONIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; DOCOSAHEXAENOIC ACID; POLYUNSATURATED FATTY ACID;

ADULT; ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; CONTROLLED STUDY; DEPRESSION; DRUG DOSE COMPARISON; DRUG TREATMENT FAILURE; FIBROMYALGIA; HYPERALGESIA; IMMOBILITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENSITIZATION; SPINAL CORD; THALAMUS; TISSUE DISTRIBUTION; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HEAT; METABOLISM; NOCICEPTIVE PAIN; PATHOPHYSIOLOGY; TOUCH; AMINO ACID BRAIN LEVEL; CHRONIC DRUG ADMINISTRATION; DOPAMINE BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; FORCED SWIM TEST; HEAT SENSITIVITY; HOT PLATE TEST; NEUROCHEMISTRY; SEROTONIN BRAIN LEVEL;

ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; DOPAMINE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HOT TEMPERATURE; HYPERALGESIA; MALE; MICE; NOCICEPTIVE PAIN; PREGABALIN; SEROTONIN; SPINAL CORD; TOUCH;

EID: 84904567443     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.05.043     Document Type: Article

References (62)

1. S. Abdelmoaty, G. Wigerblad, D.B. Bas, S. Codeluppi, T. Fernandez-Zafra, S. El-Awady el, Y. Moustafa, D. Abdelhamid Ael, E. Brodin, and C.I. Svensson Spinal actions of lipoxin A4 and 17(R)-resolvin D1 attenuate inflammation-induced mechanical hypersensitivity and spinal TNF release PloS One 8 2013 e75543
2. C. Alonso-Blanco, C. Fernandez-de-Las-Penas, A.I. de-la-Llave-Rincon, P. Zarco-Moreno, F. Galan-Del-Rio, and P. Svensson Characteristics of referred muscle pain to the head from active trigger points in women with myofascial temporomandibular pain and fibromyalgia syndrome J. Headache Pain 13 2012 625 637
3. V. Arora, and K. Chopra Possible involvement of oxido-nitrosative stress induced neuro-inflammatory cascade and monoaminergic pathway: underpinning the correlation between nociceptive and depressive behaviour in a rodent model J. Affect. Disord. 151 2013 1041 1052
4. S. Bang, S. Yoo, T.J. Yang, H. Cho, and S.W. Hwang 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception Br. J. Pharmacol. 165 2012 683 692
5. L. Bateman, R.H. Palmer, J.M. Trugman, and Y. Lin Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study J. Pain Res. 6 2013 311 318
6. A.F. Bento, R.F. Claudino, R.C. Dutra, R. Marcon, and J.B. Calixto Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice J. Immunol. 187 2011 1957 1969
7. J.D. Brederson, M.F. Jarvis, P. Honore, and C.S. Surowy Fibromyalgia: mechanisms, current treatment and animal models Curr. Pharm. Biotechnol. 12 2011 1613 1626
8. J.W. Busse, S. Ebrahim, G. Connell, E.A. Coomes, P. Bruno, K. Malik, D. Torrance, T. Ngo, K. Kirmayr, D. Avrahami, J.J. Riva, P. Struijs, D. Brunarski, S.J. Burnie, F. LeBlanc, I.A. Steenstra, Q. Mahood, K. Thorlund, V.M. Montori, V. Sivarajah, P. Alexander, M. Jankowski, W. Lesniak, M. Faulhaber, M.M. Bala, S. Schandelmaier, and G.H. Guyatt Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol Syst. Rev. 2 2013 18
9. X.J. Caro, E.F. Winter, and A.J. Dumas A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg Rheumatol. Oxf. 47 2008 208 211 (Pubitemid 351168234)
10. X.J. Caro, and E.F. Winter Evidence of abnormal epidermal nerve fiber density in fibromyalgia: clinical and immunologic implications Arthritis Rheum. 2014 10.1002/art.38662
11. M. Carta, V. Ruggiero, F. Sancassiani, F. Cutrano, A. Manca, M. Peri, A. Fais, and E. Cacace The use of antidepressants in the long-term treatment should not improve the impact of fibromyalgia on quality of life Clin. Pract. Epidemiol. Ment. Health 9 2013 120 124
12. M. Ceko, M.C. Bushnell, and R.H. Gracely Neurobiology underlying fibromyalgia symptoms Pain Res. Treatment 2012 2012 585419
13. S.R. Chaplan, F.W. Bach, J.W. Pogrel, J.M. Chung, and T.L. Yaksh Quantitative assessment of tactile allodynia in the rat paw J. Neurosci. Methods 53 1994 55 63 (Pubitemid 24238751)
14. A.H. de Souza, C.J. Castro Jr., F.K. Rigo, S.M. de Oliveira, R.S. Gomez, D.M. Diniz, M.H. Borges, M.N. Cordeiro, M.A. Silva, J. Ferreira, and M.V. Gomez An evaluation of the antinociceptive effects of Phalpha1beta, a neurotoxin from the spider Phoneutria nigriventer, and omega-conotoxin MVIIA, a cone snail Conus magus toxin, in rat model of inflammatory and neuropathic pain Cell. Mol. Neurobiol. 33 2013 59 67
15. A.H. de Souza, A.M. da Costa Lopes, C.J. Castro Jr., E.M. Pereira, C.P. Klein, C.A. da Silva Jr., J.F. da Silva, J. Ferreira, and M.V. Gomez The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model Toxicon 81C 2014 37 42
16. J.M. Desantana, K.M. da Cruz, and K.A. Sluka Animal models of fibromyalgia Arthritis Res. Therapy 15 2013 222
17. W.J. Dixon Efficient analysis of experimental observations Annu. Rev. Pharmacol. Toxicol. 20 1980 441 462
18. B. Feng, J.H. La, E.S. Schwartz, and G.F. Gebhart Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome Am. J. Physiol. Gastrointest. Liver Physiol. 302 2012 G1085 G1098
19. R.R. Gonzalez, R.F. Fernandez, J.L. Vidal, A.G. Frenich, and M.L. Perez Development and validation of an ultra-high performance liquid chromatography-tandem mass-spectrometry (UHPLC-MS/MS) method for the simultaneous determination of neurotransmitters in rat brain samples J. Neurosci. Methods 198 2011 187 194
20. R.H. Gracely, F. Petzke, J.M. Wolf, and D.J. Clauw Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia Arthritis Rheum. 46 2002 1333 1343 (Pubitemid 34525843)
21. R.E. Harris Elevated excitatory neurotransmitter levels in the fibromyalgia brain Arthritis Res. Therapy 12 2010 141
22. L. Huang, C.F. Wang, C.N. Serhan, and G. Strichartz Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1 Pain 152 2011 557 565
23. S. Hunskaar, O.G. Berge, and K. Hole A modified hot-plate test sensitive to mild analgesics Behav. Brain Res. 21 1986 101 108 (Pubitemid 16042814)
24. K.B. Jensen, R. Loitoile, E. Kosek, F. Petzke, S. Carville, P. Fransson, H. Marcus, S.C. Williams, E. Choy, Y. Mainguy, O. Vitton, R.H. Gracely, R. Gollub, M. Ingvar, and J. Kong Patients with fibromyalgia display less functional connectivity in the brain's pain inhibitory network Mol. Pain 8 2012 32
25. R.R. Ji, Z.Z. Xu, G. Strichartz, and C.N. Serhan Emerging roles of resolvins in the resolution of inflammation and pain Trends Neurosci. 34 2011 599 609
26. L.H. Jiang, Q.Y. Liang, and Y. Shi Pure docosahexaenoic acid can improve depression behaviors and affect HPA axis in mice Eur. Rev. Med. Pharmacol. Sci. 16 2012 1765 1773
27. D. Kadetoff, J. Lampa, M. Westman, M. Andersson, and E. Kosek Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels J. Neuroimmunol. 242 2012 33 38
28. D. Karaiskos, D. Pappa, E. Tzavellas, K. Siarkos, E. Katirtzoglou, G.N. Papadimitriou, and A. Politis Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study Int. J. Geriatr. Psychiatry 28 2013 100 105
29. S.C. Kim, J.E. Landon, and D.H. Solomon Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin or pregabalin Arthritis Care Res. 2013
30. D. Le Bars, M. Gozariu, and S.W. Cadden Animal models of nociception Pharmacol. Rev. 53 2001 597 652 (Pubitemid 33136239)
31. J.F. Lima-Garcia, R.C. Dutra, K. da Silva, E.M. Motta, M.M. Campos, and J.B. Calixto The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats Br. J. Pharmacol. 164 2011 278 293
32. I.S. Maciel, R.B. Silva, F.B. Morrone, J.B. Calixto, and M.M. Campos Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice PloS One 8 2013 e77227
33. C.J. Malemud Focus on pain mechanisms and pharmacotherapy in the treatment of fibromyalgia syndrome Clin. Exp. Rheumatol. 27 2009 S86 S91
34. D.A. Marcus, C.D. Bernstein, A. Haq, and P. Breuer Including a range of outcome targets offers a broader view of fibromyalgia treatment outcome: results from a retrospective review of multidisciplinary treatment Musculoskelet. Care 2013
35. P.J. Mease, K. Dundon, and P. Sarzi-Puttini Pharmacotherapy of fibromyalgia Best Pract. Research. Clin. Rheumatol. 25 2011 285 297
36. Y. Nagakura, T. Oe, T. Aoki, and N. Matsuoka Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia Pain 146 2009 26 33
37. Y. Nagakura, M. Takahashi, T. Noto, T. Sekizawa, T. Oe, E. Yoshimi, K. Tamaki, and Y. Shimizu Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: comparison of reserpine-induced myalgia and chronic constriction injury rats Behav. Brain Res. 226 2012 242 249
38. J.C. Nickel, D.A. Tripp, M. Pontari, R. Moldwin, R. Mayer, L.K. Carr, R. Doggweiler, C.C. Yang, N. Mishra, and J. Nordling Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome J. Urol. 184 2010 1358 1363
39. S. Ogino, Y. Nagakura, M. Tsukamoto, T. Watabiki, T. Ozawa, T. Oe, Y. Shimizu, and H. Ito Systemic administration of 5-HT(2C) receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model Pharmacol. Biochem. Behav. 108 2013 8 15
40. C.K. Park, Z.Z. Xu, T. Liu, N. Lu, C.N. Serhan, and R.R. Ji Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1 J. Neurosci. Off. J. Soc. Neurosci. 31 2011 18433 18438
41. D.L. Petersel, V. Dror, and R. Cheung Central amplification and fibromyalgia: disorder of pain processing J. Neurosci. Res. 89 2011 29 34
42. F. Quan-Xin, F. Fan, F. Xiang-Ying, L. Shu-Jun, W. Shi-Qi, L. Zhao-Xu, Z. Xu-Jie, Z. Qing-Chuan, and W. Wei Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia, phosphorylation of NMDA receptors, and cytokines expression in the thoracic spinal dorsal horn BMC Gastroenterol. 12 2012 148
43. N.L. Quintao, G.F. Passos, R. Medeiros, A.F. Paszcuk, F.L. Motta, J.B. Pesquero, M.M. Campos, and J.B. Calixto Neuropathic pain-like behavior after brachial plexus avulsion in mice: the relevance of kinin B1 and B2 receptors J. Neurosci. Off. J. Soc. Neurosci. 28 2008 2856 2863 (Pubitemid 351398888)
44. T. Roth, L.M. Arnold, D. Garcia-Borreguero, M. Resnick, and A.G. Clair A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions Sleep. Med. Rev. 2013
45. T. Schmidt-Wilcke, and D.J. Clauw Fibromyalgia: from pathophysiology to therapy Nat. Reviews. Rheumatol. 7 2011 518 527
46. C.N. Serhan, and N. Chiang Resolution phase lipid mediators of inflammation: agonists of resolution Curr. Opin. Pharmacol. 13 2013 632 640
47. M. Sisignano, D.L. Bennett, G. Geisslinger, and K. Scholich TRP-channels as key integrators of lipid pathways in nociceptive neurons Prog. Lipid Res. 53C 2013 93 107
48. H.S. Smith, R. Harris, and D. Clauw Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome Pain Physician 14 2011 E217 E245
49. M.T. Smith, and B.J. Moore Pregabalin for the treatment of fibromyalgia Expert Opin. Pharmacother. 13 2012 1527 1533
50. C. Sommer, and F. Birklein Fighting off pain with resolvins Nat. Med. 16 2010 518 520
51. R. Staud Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases Curr. Rheumatol. Rep. 14 2012 539 548
52. N. Üçeyler, W. Hauser, and C. Sommer Systematic review with meta-analysis: cytokines in fibromyalgia syndrome BMC Musculoskelet. Disorders 12 2011 245
53. N. Üçeyler, R. Valenza, M. Stock, R. Schedel, G. Sprotte, and C. Sommer Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain Arthritis Rheum. 54 2006 2656 2664 (Pubitemid 44205028)
54. N. Üçeyler, D. Zeller, A.K. Kahn, S. Kewenig, S. Kittel-Schneider, A. Schmid, J. Casanova-Molla, K. Reiners, and C. Sommer Small fibre pathology in patients with fibromyalgia syndrome Brain 136 2013 1857 1867
55. M.M. Valente, V. Bortolotto, B. Cuccurazzu, F. Ubezio, V. Meneghini, M.T. Francese, P.L. Canonico, and M. Grilli alpha2delta ligands act as positive modulators of adult hippocampal neurogenesis and prevent depression-like behavior induced by chronic restraint stress Mol. Pharmacol. 82 2012 271 280
56. T. Veselinović, H. Schorn, I. Vernaleken, K. Schiffl, C. Hiemke, G. Zernig, R. Gur, and G. Gründer Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers Psychopharmacol. Berl. 2011 218733 218748
57. T. Veselinović, H. Schorn, I.B. Vernaleken, C. Hiemke, G. Zernig, R. Gur, and G. Gründer Effects of antipsychotic treatment on cognition in healthy subjects J. Psychopharmacol. 27 2013 374 385
58. J. Wallin, J.G. Cui, V. Yakhnitsa, G. Schechtmann, B.A. Meyerson, and B. Linderoth Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy Eur. J. Pain 6 2002 261 272 (Pubitemid 35177563)
59. F. Wolfe, D.J. Clauw, M.A. Fitzcharles, D.L. Goldenberg, R.S. Katz, P. Mease, A.S. Russell, I.J. Russell, J.B. Winfield, and M.B. Yunus The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity Arthritis Care Res. 62 2010 600 610
60. M.X. Xu, B.C. Tan, W. Zhou, T. Wei, W.H. Lai, J.W. Tan, and J.H. Dong Resolvin D1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathways in microglial cells, prevents lipopolysaccharide-induced inflammatory responses CNS Neurosci. Therap. 19 2013 235 243
61. Y. Xu, L. Zhang, T. Shao, L. Ruan, L. Wang, J. Sun, J. Li, X. Zhu, J.M. O'Donnell, and J. Pan Ferulic acid increases pain threshold and ameliorates depression-like behaviors in reserpine-treated mice: behavioral and neurobiological analyses Metab. Brain Dis. 28 2013 571 583
62. Z.Z. Xu, L. Zhang, T. Liu, J.Y. Park, T. Berta, R. Yang, C.N. Serhan, and R.R. Ji Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions Nat. Med. 16 2010 592 597 Nível Superior